<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Prazosin: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Prazosin: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Prazosin: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="9806" href="/d/html/9806.html" rel="external">see "Prazosin: Drug information"</a> and <a class="drug drug_patient" data-topicid="10990" href="/d/html/10990.html" rel="external">see "Prazosin: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F212751"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Minipress</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52868006"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>APO-Prazo;</li>
<li>Minipress;</li>
<li>TEVA-Prazosin</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1055005"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Alpha-Adrenergic Blocking Agent, Oral</span>;</li>
<li>
<span class="list-set-name">Antihypertensive Agent</span>;</li>
<li>
<span class="list-set-name">Vasodilator</span></li></ul></div>
<div class="block dop drugH1Div" id="F212764"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="bc4b3de7-1b7f-4f34-9c5e-fb2c0aab85f9">Hypertension</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypertension:</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Not recommended first-line therapy; reserve for patients not responsive to therapeutic trials of 2 or more preferred agents (eg, ACE inhibitor, ARB, calcium channel blocker, or thiazide diuretic) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28827377']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28827377'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children and Adolescents: Oral: Initial: 0.05 to 0.1 mg/kg/<b>day</b> in divided doses every 8 hours; may titrate up to 0.5 mg/kg/<b>day</b> in divided doses 3 times daily; maximum daily dose: 20 mg/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15286277','lexi-content-ref-NHLBI.2011']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15286277','lexi-content-ref-NHLBI.2011'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9e288f4c-9e8a-4c01-9b48-9eeed22f9317">Scorpion envenomation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Scorpion envenomation:</b> Limited data available; multiple regimens reported:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Dosing based on small studies and case series/reports that describe positive effects of prazosin in the management of the sympathetic stimulatory cardiovascular effects of scorpion envenomation, usually due to stings from non-<i>Centruroides</i> species typically found outside North America (eg, India [<i>M. tamulus</i>], Africa [<i>L. quinquestriatus</i>], Middle East [<i>A. crassicauda</i>]) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33005956','lexi-content-ref-25075837','lexi-content-ref-28390429']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33005956','lexi-content-ref-25075837','lexi-content-ref-28390429'])">Ref</a></span>). Scorpion antivenom has been used in conjunction with prazosin, and the combination was reported to be more beneficial than antivenom alone in some instances (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24550184','lexi-content-ref-28390429']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24550184','lexi-content-ref-28390429'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Weight-directed dosing:</i> Infants ≥4 months, Children, and Adolescents: Oral: 0.03 mg/kg/dose every 3 to 6 hours; reported administration schedule for dosing interval and length of therapy are variable; in general, therapy continued until extremities were warm and dry (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19812121','lexi-content-ref-19710245','lexi-content-ref-25624650','lexi-content-ref-24550184']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19812121','lexi-content-ref-19710245','lexi-content-ref-25624650','lexi-content-ref-24550184'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Fixed dosing:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Infants &gt;6 months and Children &lt;12 years: Oral: 0.25 mg every 3 hours until extremities are warm and dry (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21209062','lexi-content-ref-25075837']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21209062','lexi-content-ref-25075837'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥12 years and Adolescents:</p>
<p style="text-indent:-2em;margin-left:8em;">≤20 kg: Oral: 0.25 to 0.5 mg every 3 hours until extremities are warm and dry (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21209062','lexi-content-ref-20935398']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21209062','lexi-content-ref-20935398'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">&gt;20 kg: Oral: 0.25 to 1 mg every 3 hours until extremities are warm and dry (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21209062','lexi-content-ref-25075837','lexi-content-ref-20935398']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21209062','lexi-content-ref-25075837','lexi-content-ref-20935398'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51154929"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling. Based on experience in adults, initiation at lower dosages suggested; titrate cautiously (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aronoff.2007']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aronoff.2007'])">Ref</a></span>).</p></div>
<div class="block dohp drugH1Div" id="F51154930"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doa drugH1Div" id="F212756"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9806" href="/d/html/9806.html" rel="external">see "Prazosin: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4f0c92d9-ad08-4643-a848-3296ddf5258e">Hypertension, chronic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypertension, chronic (alternative agent):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Not recommended for initial management but may be considered as additional therapy for resistant hypertension in patients who do not respond adequately to combination therapy with preferred agents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29133354']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29133354'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 1 mg 2 or 3 times daily; titrate as needed based on patient response up to 20 mg/day in 2 or 3 divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29133354']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29133354'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b74ae7ce-b719-42e8-bc38-6773c06cafe6">PTSD-related nightmares and sleep disruption</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>PTSD-related nightmares and sleep disruption (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 1 mg at bedtime; after 2 to 3 days increase dose to 2 mg at bedtime, then adjust dosage based on response and tolerability in 1 to 5 mg increments every 7 days up to a maximum of 15 mg/day. Titration as rapid as every 2 to 3 days has been evaluated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27828694']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27828694'])">Ref</a></span>). Usual dose range: 3 to 15 mg at bedtime (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Benedek.2009']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Benedek.2009'])">Ref</a></span>). Civilian patients, especially females, may require lower doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17868655']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17868655'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="fed0e48d-298d-453f-bda8-97189c608a2d">Raynaud phenomenon</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Raynaud phenomenon (alternative agent) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note</b>: Effects may be transient and may become less effective over several weeks; consider an alternative agent (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12324557']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12324557'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 0.5 to 1 mg once daily (at bedtime) <b>or</b> 0.5 mg twice daily; gradually adjust dose based on response and tolerability up 12 mg/day in 2 to 3 divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6345178','lexi-content-ref-3884807','lexi-content-ref-12324557','lexi-content-ref-3243924']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6345178','lexi-content-ref-3884807','lexi-content-ref-12324557','lexi-content-ref-3243924'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990732"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>eGFR ≥60 mL/minute/1.73 m<sup>2</sup>:</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7379445','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7379445','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>eGFR &lt;60 mL/minute/1.73 m<sup>2</sup>:</b> Although pharmacokinetic parameters are not significantly altered, BP-lowering effects may be exaggerated in patients with kidney impairment; begin at low dosages; titrate cautiously (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3792430','lexi-content-ref-7379445']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3792430','lexi-content-ref-7379445'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Unlikely to be dialyzed (highly protein bound): Although pharmacokinetic parameters are not significantly altered, BP-lowering effects may be exaggerated in patients with kidney impairment; begin at low dosages; titrate cautiously (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7379445','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7379445','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Unlikely to be dialyzed (highly protein bound): Although pharmacokinetic parameters are not expected to be significantly altered, BP-lowering effects may be exaggerated in patients with kidney impairment; begin at low dosages; titrate cautiously (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b> Although pharmacokinetic parameters are not expected to be significantly altered, BP-lowering effects may be exaggerated in patients with kidney impairment; begin at low dosages; titrate cautiously (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b> Although pharmacokinetic parameters are not expected to be significantly altered, BP-lowering effects may be exaggerated in patients with kidney impairment; begin at low dosages; titrate cautiously (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988099"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block arsc drugH1Div" id="F57027853"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Floppy iris syndrome</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Intraoperative floppy iris syndrome </b>(IFIS) has been reported in patients with current or prior use of alpha-1 blockers undergoing cataract surgery (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15899440','lexi-content-ref-17318207','lexi-content-ref-19668424','lexi-content-ref-24917702']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15899440','lexi-content-ref-17318207','lexi-content-ref-19668424','lexi-content-ref-24917702'])">Ref</a></span>). Studies report significantly higher surgical complication rates for patients who experience IFIS (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24917702']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24917702'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Not completely established; may be related to a combination of the pharmacologic action (ie, inhibition of the iris dilator smooth muscle contraction) and long-term smooth muscle atrophy from accumulation in iris pigment epithelial cells (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29732214','lexi-content-ref-25073735']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29732214','lexi-content-ref-25073735'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; may occur with current (within a few days to months of initiation) or prior use (years following discontinuation) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25073735','lexi-content-ref-18388959','lexi-content-ref-24917702']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25073735','lexi-content-ref-18388959','lexi-content-ref-24917702'])">Ref</a></span>). A minimum 3-month duration of alpha-1 blocker use has been proposed as a risk for IFIS (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16863971','lexi-content-ref-18388959']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16863971','lexi-content-ref-18388959'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Individual alpha-1 blocker (risk highest with tamsulosin) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19668424']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19668424'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Hypertension (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21168223']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21168223'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Males (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32109982']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32109982'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Older age (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32109982']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32109982'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Decreased preoperative dilated pupil diameter (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32109982']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32109982'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Orthostatic hypotension</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Prazosin is associated with <b>orthostatic hypotension</b>, which can manifest as <b>dizziness </b>and <b>vertigo</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31327266','lexi-content-ref-8931848','lexi-content-ref-6162595']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31327266','lexi-content-ref-8931848','lexi-content-ref-6162595'])">Ref</a></span>). One study suggests that orthostatic hypotension may be transient (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6162595']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6162595'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose-related; related to the pharmacologic action (ie, inhibition of vascular smooth muscle contraction and vasodilation) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19077827']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19077827'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; “first dose” orthostatic hypotension may occur 30 minutes to 3 hours after dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6162595']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6162595'])">Ref</a></span>). However, has also occurred months after initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31327266']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31327266'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Individual alpha-1 blocker (risk lowest with tamsulosin) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10364649']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10364649'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• First dose or redose after dose interruption (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25073735','lexi-content-ref-8931848']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25073735','lexi-content-ref-8931848'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Rapid increase in dose</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent medications that cause orthostatic hypotension (eg, antihypertensives, nitrates, phosphodiesterase-5 inhibitors) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25073735']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25073735'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Females &gt;65 years of age (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31327266']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31327266'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Alcohol use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27551761']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27551761'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F212719"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Edema (1% to 4%), orthostatic hypotension (1% to 4%), palpitations (5%), syncope (1% to 4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash (1% to 4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Constipation (1% to 4%), diarrhea (1% to 4%), nausea (5%), vomiting (1% to 4%), xerostomia (1% to 4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Urinary frequency (1% to 4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Asthenia (7%), depression (1% to 4%), dizziness (10%), drowsiness (8%), fatigue (7%), headache (8%), nervousness (1% to 4%), vertigo (1% to 4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blurred vision (1% to 4%), injected sclera (1% to 4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dyspnea (1% to 4%), epistaxis (1% to 4%), nasal congestion (1% to 4%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Tachycardia</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia, diaphoresis, lichen planus, pruritus</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal distress, abdominal pain, pancreatitis</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Impotence, priapism, urinary incontinence</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Positive ANA titer</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Abnormal hepatic function tests</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Hallucination, paresthesia</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Tinnitus</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Angina pectoris (including exacerbation of angina pectoris) (Charness 1979), bradycardia (Ball 1994), flushing, vasculitis</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Urticaria (Ruzicka 1983)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Gynecomastia</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Insomnia, malaise, narcolepsy (exacerbation), pain</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Cataract, eye pain, intraoperative floppy iris syndrome (cataract surgery) (Issa 2008), retinal pigment changes (mottled), retinopathy (serous)</p></div>
<div class="block coi drugH1Div" id="F212734"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Known sensitivity to quinazolines, prazosin, or any component of the formulation</p></div>
<div class="block war drugH1Div" id="F212716"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Angina: Discontinue if symptoms of angina occur or worsen.</p>
<p style="text-indent:-2em;margin-left:4em;">• CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks that require mental alertness (eg, operating machinery or driving).</p>
<p style="text-indent:-2em;margin-left:4em;">• Floppy iris syndrome: Intraoperative floppy iris syndrome has been observed in cataract surgery patients who were on or were previously treated with alpha<sub>1</sub>-blockers; modification to surgical technique may be necessary. There appears to be no benefit in discontinuing alpha<sub>1</sub>-blockers prior to surgery.</p>
<p style="text-indent:-2em;margin-left:4em;">• Orthostatic hypotension/syncope: May cause significant orthostatic hypotension and syncope with sudden loss of consciousness, especially within 30 to 90 minutes of the first dose; anticipate a similar effect if therapy is interrupted for a few days, if dosage is rapidly increased, or if another antihypertensive drug (particularly vasodilators or a beta-blocker) or a phosphodiesterase 5 (PDE 5) inhibitor (eg, sildenafil, tadalafil, vardenafil) is introduced. Severe tachycardia (120 to 160 beats/minute) has occasionally been reported prior to a syncopal episode. Patients should be cautioned about alcohol use and performing hazardous tasks when starting new therapy or adjusting dosage upward.</p>
<p style="text-indent:-2em;margin-left:4em;">• Priapism: Priapism and prolonged erections have been reported; seek immediate medical assistance for erections lasting longer than 4 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Heart failure: In a scientific statement from the American Heart Association, prazosin has been determined to be an agent that may exacerbate underlying myocardial dysfunction (magnitude: moderate) (AHA [Page 2016]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Prostate cancer: Should rule out prostatic carcinoma before beginning therapy.</p></div>
<div class="block foc drugH1Div" id="F212728"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Minipress: 1 mg, 2 mg, 5 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1 mg, 2 mg, 5 mg</p></div>
<div class="block geq drugH1Div" id="F212712"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F212736"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Minipress Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 mg (per each): $2.78</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2 mg (per each): $3.87</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg (per each): $6.59</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Prazosin HCl Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 mg (per each): $0.07 - $1.81</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2 mg (per each): $0.10 - $2.52</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg (per each): $0.15 - $5.41</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52868007"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Minipress: 1 mg [contains fd&amp;c yellow #6 (sunset yellow)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Minipress: 2 mg, 5 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1 mg, 2 mg, 5 mg</p></div>
<div class="block admp drugH1Div" id="F52613651"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: Administer without regard to meals at the same time each day.</p></div>
<div class="block sts drugH1Div" id="F212746"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;margin-left:0em;text-align:justify;display:inline">Store at 20°C to 25°C (68°F to 77°F). Protect from moisture and light.</p></div>
<div class="block usep drugH1Div" id="F53568499"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of hypertension alone or in combination with diuretics or beta-blockers (FDA approved in adults); has also been used in the management of the sympathetic stimulatory cardiovascular effects of scorpion envenomation, usually due to stings from non-<i>Centruroides</i> species typically found outside North America (eg, India [<i>Mesobuthus tamulus</i>], Middle East [<i>Leiurus</i>
<i>quinquestriatus</i>], and North Africa [<i>Androctonus crassicauda</i>]).</p></div>
<div class="block mst drugH1Div" id="F212778"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Prazosin may be confused with predniSONE</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Older Adult: High-Risk Medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Beers Criteria: Prazosin is identified in the Beers Criteria as a potentially inappropriate medication for hypertension in patients 65 years and older due to its high risk of orthostatic hypotension. Avoid use for hypertension treatment (alternative agents have superior risk-benefit profiles) (Beers Criteria [AGS 2023]).</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F9838452"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F212721"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alpha-/Beta-Agonists: Alpha1-Blockers may diminish the vasoconstricting effect of Alpha-/Beta-Agonists. Similarly, Alpha-/Beta-Agonists may antagonize Alpha1-Blocker vasodilation. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alpha1-Agonists: Alpha1-Blockers may diminish the vasoconstricting effect of Alpha1-Agonists. Similarly, Alpha1-Agonists may antagonize Alpha1-Blocker vasodilation. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alpha1-Blockers: May enhance the antihypertensive effect of other Alpha1-Blockers.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When used at chemotherapy doses, hold blood pressure lowering medications for 24 hours before amifostine administration. If blood pressure lowering therapy cannot be held, do not administer amifostine. Use caution with radiotherapy doses of amifostine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amphetamines: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antihypertensive Agents: May enhance the hypotensive effect of Prazosin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Arginine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benperidol: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brigatinib: May diminish the antihypertensive effect of Antihypertensive Agents. Brigatinib may enhance the bradycardic effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May diminish the hypotensive effect of Blood Pressure Lowering Agents. Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dapoxetine: May enhance the orthostatic hypotensive effect of Alpha1-Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dexmethylphenidate: May diminish the therapeutic effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunarizine: May enhance the therapeutic effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Blood Pressure Increasing Effects: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Blood Pressure Lowering Effects: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levodopa-Foslevodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa-Foslevodopa. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Loop Diuretics: May enhance the hypotensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methylphenidate: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Alpha1-Blockers (Nonselective). Management: Ensure patient is stable on one agent prior to initiating the other, and always initiate combination using the lowest possible dose of the drug being added. When tadalafil is used for treatment of BPH, concurrent alpha 1-blockers are not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rilmenidine: Alpha1-Blockers may enhance the hypotensive effect of Rilmenidine. <i> Risk C: Monitor therapy</i></p></div>
<div class="block foi drugH1Div" id="F212747"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;text-align:justify;display:inline">Food has variable effects on absorption. Management: Administer without regard to food.</p></div>
<div class="block rep_considerations drugH1Div" id="F58106453"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;display:inline">Medications considered acceptable for the treatment of chronic hypertension during pregnancy may generally be continued in patients trying to conceive. Prazosin is not considered a preferred agent for use in pregnant patients; consider transitioning to a preferred agent in patients planning to become pregnant (ACC/AHA [Whelton 2018]; ACOG 2019; NICE 2019).</p></div>
<div class="block pri drugH1Div" id="F13459610"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Prazosin crosses the placenta (Bourget 1995).</p>
<p style="text-indent:0em;margin-top:2em;">Chronic maternal hypertension is associated with adverse events in the fetus/infant. Chronic maternal hypertension may increase the risk of birth defects, low birth weight, premature delivery, stillbirth, and neonatal death. Actual fetal/neonatal risks may be related to the duration and severity of maternal hypertension. Untreated chronic hypertension may also increase the risks of adverse maternal outcomes, including gestational diabetes, preeclampsia, delivery complications, stroke, and myocardial infarction (ACOG 2019).</p>
<p style="text-indent:0em;margin-top:2em;">Due to pregnancy-induced physiologic changes, some pharmacokinetic properties of prazosin may be altered (Bourget 1995; Rubin 1983).</p>
<p style="text-indent:0em;margin-top:2em;">Patients with preexisting hypertension may continue their medication during pregnancy unless contraindications exist (ESC [Regitz-Zagrosek 2018]). When treatment of chronic hypertension during pregnancy is initiated during pregnancy, agents other than prazosin may be preferred (ACOG 2019; ESC [Cífková 2020]; ESC [Regitz-Zagrosek 2018]; SOGC [Magee 2022]); if needed, use of prazosin should be considered in consult with subspecialists (ACOG 2019).</p>
<p style="text-indent:0em;margin-top:2em;">Untreated hypertension due to a pheochromocytoma during pregnancy is associated with a high rate of maternal and fetal mortality therefore treatment is recommended (ESC [Cífková 2020]). Case reports describe the use of prazosin as part of combination therapy for the treatment of hypertension due to pheochromocytoma in pregnant patients (Agrawal 2022). Prazosin may be an alternative option for the treatment of hypertension due to pheochromocytoma during pregnancy (Pacu 2021).</p></div>
<div class="block mopp drugH1Div" id="F53568478"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Blood pressure (standing and sitting or supine).</p></div>
<div class="block pha drugH1Div" id="F212715"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Competitively inhibits postsynaptic alpha-adrenergic receptors which results in vasodilation of veins and arterioles and a decrease in total peripheral resistance and blood pressure</p></div>
<div class="block phk drugH1Div" id="F212733"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Onset of action: Antihypertensive: Within 2 hours; Peak effect: 2 to 4 hours</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Duration of action: 10 to 24 hours </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Distribution: V<sub>d</sub>: 0.5 L/kg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Protein binding: Highly bound (97%)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism: Extensively hepatic via demethylation and conjugation</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Bioavailability: 43% to 82%</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination: 2 to 3 hours, prolonged with CHF </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Time to peak, plasma: ~3 hours</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Feces; urine (6% to 10% as unchanged drug)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F212737"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Apo prazo | Minipress</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Decliten | Minipres</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Minipress</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Cm prazosin | Dbl prazosin | GenRx Prazosin | Minipress | Prasig | Pratsiol | Prazohexal | Prazosin | Prazosin-bc | Pressin | Tw prazosin</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Alphapress | Prazolok | Prazopress</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Minipress</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Prazosin</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Minipress</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Minipress</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Minipress</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Prazosin</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Minipres | Praten | Prazosina</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Adversuten | Deprazolin | Minipress</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Adversuten | Duramipress | Eurex | Minipres | Minipress | Prazosin | Prazosin Atid</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Decliten | Minipres</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Adversuten | Minipres | Minipress | Pratsiol | Prazosin | Prazosin Heumann</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Minipress</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Minipres</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Patsolin | Peripress | Pratsiol | Prazocor</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Minipress | Prazosine Dci</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Alphavase | Hypovase | Prazosin | Prazosin cox | Prazosin kent | Sinetens</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Minipress</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Apo prazo | Cp-Prazo | Hyprosin | Minipress | Pratsiol | Prazon plus | Prazosin</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Huma-prazin | Minipress</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Minipress | Prazosin | Rexibet</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Hypovase</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Hypotens</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Cyber | Minipress xl | Prazocip | Prazocip-xl | Prazonic xl | Prazopress | Prazothem | Prazothem er | Prozoten | Renopress | Renopress xl | Unipraz</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Coltock | Daldanon | Daldanon choseido | Downat | Downat taiyo | Downpress zensei | Enzosine | Fellhye | Flaboido | Isepress isei | Isepress teisan | Kachilet | Metrasen | Minipress | Mizpiron | Neprozon | Queenpress | Sedaxin | Stroken | Trabuzon</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Minecin | Minesin | Minipress | Prazosin</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Minipress</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Minipress</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Adversuten | Apo prazo | Deprazolin | Minipress | Polpressin | Pratsiol | Prazosin</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Minipress</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Adversuten | Deprazolin | Minipress | Polpressin | Pratsiol | Prazosin</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Aponazo | Lesaprin | Minipres | Minipress | Ozpre | Prabioquim</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Atodel | Lopresin | Minipress | Minison | Mizosin | Prazosin | Prazosin Hexal | Prazotab</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Minipres | Minipress | Prazosine</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Apo prazo | Hypovase | Minipress | Pratsiol | Prazosin hcl teva</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Apo prazosin | Hyprosin | Pratsiol</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Minipress</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Minipress</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Adversuten | Deprazolin | Eurex | Minipress | Polpressin</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Minipress | Prazosin | Prazosin HCL</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Prazosina</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Atodel</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Adversuten | Hypotens | Minipress</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Adversuten | Minipress | Polpressin | Prazosin | Prazozinbene</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Minipress</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Apo prazo | Atodel | Minipress | Mizosin | Pratsiol</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Vasoflex</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Deprazolin</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Apo prazo | Atodel | Bypress | Hypopress | Hyposin | Lopress | Minipress | Mysial | Parabowl | Polypress | Prapress | Pratsiol | Prazomed | Prazopress | Prazosin | Pressin | Simpress</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Minipress</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Minipress</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Damin | Hyprosin | Minipress | Minison | Nilpress | Pratsiol</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Prazosin Ratiopharm</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Minipres</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Minpres</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Minipress | Pratsiol</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Prozotab</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Variprex</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-37139824">
<a name="37139824"></a>2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2023;71(7):2052-2081. doi:10.1111/jgs.18372<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prazosin-pediatric-drug-information/abstract-text/37139824/pubmed" id="37139824" target="_blank">37139824</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19077827">
<a name="19077827"></a>Abdel-Aziz S, Mamalis N. Intraoperative floppy iris syndrome. <i>Curr Opin Ophthalmol</i>. 2009;20(1):37-41. doi:10.1097/ICU.0b013e32831bc0ad<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prazosin-pediatric-drug-information/abstract-text/19077827/pubmed" id="19077827" target="_blank">19077827</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33005956">
<a name="33005956"></a>Abdel Baseer KA, Aboelela MG, Qubaisy HM. Echocardiographic evaluation of the response to prazosin treatment in scorpion sting. <i>J Trop Pediatr</i>. 2021;67(3):fmaa063. doi:10.1093/tropej/fmaa063<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prazosin-pediatric-drug-information/abstract-text/33005956/pubmed" id="33005956" target="_blank">33005956</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35928058">
<a name="35928058"></a>Agrawal K, Walia R, Singh Jayant S, et al. Pheochromocytoma in pregnancy: a syndromic association. <i>J Obstet Gynaecol India</i>. 2022;72(Suppl 1):48-54. doi:10.1007/s13224-021-01532-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prazosin-pediatric-drug-information/abstract-text/35928058/pubmed" id="35928058" target="_blank">35928058</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30575676">
<a name="30575676"></a>American College of Obstetricians and Gynecologists (ACOG). ACOG practice bulletin no. 203: chronic hypertension in pregnancy. <i>Obstet Gynecol</i>. 2019;133(1):e26-e50. doi:10.1097/AOG.0000000000003020<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prazosin-pediatric-drug-information/abstract-text/30575676/pubmed" id="30575676" target="_blank">30575676</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Aronoff.2007">
<a name="Aronoff.2007"></a>Aronoff GR, Bennett WM, Berns JS, et al. <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>. 5th ed. Philadelphia, PA: American College of Physicians; 2007.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7903757">
<a name="7903757"></a>Ball J. Symptomatic sinus bradycardia due to prazosin. <i>Lancet</i>. 1994;343(8889):121. doi:10.1016/s0140-6736(94)90853-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prazosin-pediatric-drug-information/abstract-text/7903757/pubmed" id="7903757" target="_blank">7903757</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35900217">
<a name="35900217"></a>Bandelow B, Allgulander C, Baldwin DS, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders - version 3. Part II: OCD and PTSD. <i>World J Biol Psychiatry</i>. 2023;24(2):118-134. doi:10.1080/15622975.2022.2086296<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prazosin-pediatric-drug-information/abstract-text/35900217/pubmed" id="35900217" target="_blank">35900217</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21209062">
<a name="21209062"></a>Bawaskar HS, Bawaskar PH. Efficacy and safety of scorpion antivenom plus prazosin compared with prazosin alone for venomous scorpion (<i>Mesobuthus tamulus</i>) sting: randomised open label clinical trial. <i>BMJ</i>. 2011;342:c7136. doi:10.1136/bmj.c7136<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prazosin-pediatric-drug-information/abstract-text/21209062/pubmed" id="21209062" target="_blank">21209062</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Benedek.2009">
<a name="Benedek.2009"></a>Benedek DM, Friedman MJ, Zatzick D, et al. “Guideline Watch (March 2009): Practice Guideline for the Treatment of Patients With Acute Stress Disorder and Posttraumatic Stress Disorder.”</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19812121">
<a name="19812121"></a>Bosnak M, Levent Yilmaz H, Ece A, et al. Severe scorpion envenomation in children: Management in pediatric intensive care unit. <i>Hum Exp Toxicol</i>. 2009;28(11):721-728. doi:10.1177/0960327109350667<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prazosin-pediatric-drug-information/abstract-text/19812121/pubmed" id="19812121" target="_blank">19812121</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8751046">
<a name="8751046"></a>Bourget P, Fernandez H, Edouard D, et al. Disposition of a new rate-controlled formulation of prazosin in the treatment of hypertension during pregnancy: transplacental passage of prazosin. <i>Eur J Drug Metab Pharmacokinet</i>. 1995;20(3):233-241. doi:10.1007/BF03189675<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prazosin-pediatric-drug-information/abstract-text/8751046/pubmed" id="8751046" target="_blank">8751046</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15899440">
<a name="15899440"></a>Chang DF, Campbell JR. Intraoperative floppy iris syndrome associated with tamsulosin. <i>J Cataract Refract Surg</i>. 2005;31(4):664-673. doi:10.1016/j.jcrs.2005.02.027<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prazosin-pediatric-drug-information/abstract-text/15899440/pubmed" id="15899440" target="_blank">15899440</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21168223">
<a name="21168223"></a>Chatziralli IP, Sergentanis TN. Risk factors for intraoperative floppy iris syndrome: a meta-analysis. <i>Ophthalmology</i>. 2011;118(4):730-735. doi:10.1016/j.ophtha.2010.08.039<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prazosin-pediatric-drug-information/abstract-text/21168223/pubmed" id="21168223" target="_blank">21168223</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-472855">
<a name="472855"></a>Charness ME, Fishman JA, Robertson D. Exacerbation of angina pectoris by prazosin. <i>South Med J</i>. 1979;72(9):1213-1214. doi:10.1097/00007611-197909000-00040<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prazosin-pediatric-drug-information/abstract-text/472855/pubmed" id="472855" target="_blank">472855</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16863971">
<a name="16863971"></a>Cheung CM, Awan MA, Sandramouli S. Prevalence and clinical findings of tamsulosin-associated intraoperative floppy-iris syndrome. <i>J Cataract Refract Surg</i>. 2006;32(8):1336-1339. doi:10.1016/j.jcrs.2006.03.034<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prazosin-pediatric-drug-information/abstract-text/16863971/pubmed" id="16863971" target="_blank">16863971</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32109982">
<a name="32109982"></a>Christou CD, Tsinopoulos I, Ziakas N, Tzamalis A. Intraoperative floppy iris syndrome: Updated perspectives. <i>Clin Ophthalmol</i>. 2020;14:463-471. doi:10.2147/OPTH.S221094<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prazosin-pediatric-drug-information/abstract-text/32109982/pubmed" id="32109982" target="_blank">32109982</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31841131">
<a name="31841131"></a>Cífková R, Johnson MR, Kahan T, et al. Peripartum management of hypertension: a position paper of the ESC Council on Hypertension and the European Society of Hypertension. <i>Eur Heart J Cardiovasc Pharmacother</i>. 2020;6(6):384-393. doi:10.1093/ehjcvp/pvz082<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prazosin-pediatric-drug-information/abstract-text/31841131/pubmed" id="31841131" target="_blank">31841131</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17318207">
<a name="17318207"></a>Dhingra N, Rajkumar KN, Kumar V. Intraoperative floppy iris syndrome with doxazosin. <i>Eye (Lond)</i>. 2007;21(5):678-679. doi:10.1038/sj.eye.6702680<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prazosin-pediatric-drug-information/abstract-text/17318207/pubmed" id="17318207" target="_blank">17318207</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10364649">
<a name="10364649"></a>Djavan B, Marberger M. A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. <i>Eur Urol</i>. 1999;36(1):1-13. doi:10.1159/000019919<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prazosin-pediatric-drug-information/abstract-text/10364649/pubmed" id="10364649" target="_blank">10364649</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28827377">
<a name="28827377"></a>Flynn JT, Kaelber DC, Baker-Smith CM, et al. Clinical practice guideline for screening and management of high blood pressure in children and adolescents. <i>Pediatrics</i>. 2017;140(3). pii: e20171904. doi:10.1542/peds.2017-1904.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prazosin-pediatric-drug-information/abstract-text/28827377/pubmed" id="28827377" target="_blank">28827377</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24243703">
<a name="24243703"></a>Go AS, Bauman MA, Coleman King SM, et al; American Heart Association; American College of Cardiology; Centers for Disease Control and Prevention. An effective approach to high blood pressure control: a science advisory from the American Heart Association, the American College of Cardiology, and the Centers for Disease Control and Prevention. <i>Hypertension</i>. 2014;63(4):878-885. doi:10.1161/HYP.0000000000000003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prazosin-pediatric-drug-information/abstract-text/24243703/pubmed" id="24243703" target="_blank">24243703</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19710245">
<a name="19710245"></a>Gupta BD, Parakh M, Purohit A. Management of scorpion sting: prazosin or dobutamine. <i>J Trop Pediatr</i>. 2010;56(2):115-118. doi:10.1093/tropej/fmp070<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prazosin-pediatric-drug-information/abstract-text/19710245/pubmed" id="19710245" target="_blank">19710245</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31327266">
<a name="31327266"></a>Hiremath S, Ruzicka M, Petrcich W, et al. Alpha-blocker use and the risk of hypotension and hypotension-related clinical events in women of advanced age. <i>Hypertension</i>. 2019;74(3):645-651. doi:10.1161/HYPERTENSIONAHA.119.13289<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prazosin-pediatric-drug-information/abstract-text/31327266/pubmed" id="31327266" target="_blank">31327266</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25075837">
<a name="25075837"></a>Isbister GK, Bawaskar HS. Scorpion envenomation. <i>N Engl J Med</i>. 2014;371(5):457-463. doi:10.1056/NEJMra1401108<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prazosin-pediatric-drug-information/abstract-text/25075837/pubmed" id="25075837" target="_blank">25075837</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19668424">
<a name="19668424"></a>Issa SA, Hadid OH, Baylis O, Dayan M. Alpha antagonists and intraoperative floppy iris syndrome: A spectrum. <i>Clin Ophthalmol</i>. 2008;2(4):735-741. doi:10.2147/opth.s2697<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prazosin-pediatric-drug-information/abstract-text/19668424/pubmed" id="19668424" target="_blank">19668424</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24352797">
<a name="24352797"></a>James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8) [published correction appearing in <i>JAMA</i>. 2014 May 7;311(17):1809]. <i>JAMA</i>. 2014;5;311(5):507-520. doi:10.1001/jama.2013.284427<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prazosin-pediatric-drug-information/abstract-text/24352797/pubmed" id="24352797" target="_blank">24352797</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25624650">
<a name="25624650"></a>Kumar CM, Prasad SV. Echocardiologic evaluation and follow-up of cardiovascular complications in children with scorpion sting in coastal South India. <i>Indian J Crit Care Med</i>. 2015;19(1):42-46. doi:10.4103/0972-5229.148645<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prazosin-pediatric-drug-information/abstract-text/25624650/pubmed" id="25624650" target="_blank">25624650</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3792430">
<a name="3792430"></a>Lameire N, Gordts J. A pharmacokinetic study of prazosin in patients with varying degrees of chronic renal failure. <i>Eur J Clin Pharmacol</i>. 1986;31(3):333-337. doi:10.1007/BF00981133<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prazosin-pediatric-drug-information/abstract-text/3792430/pubmed" id="3792430" target="_blank">3792430</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34384237">
<a name="34384237"></a>Lerner LB, McVary KT, Barry MJ, et al. Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA guideline part I—initial work-up and medical management. <i>J Urol</i>. 2021;206(4):806-817. doi:10.1097/JU.0000000000002183<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prazosin-pediatric-drug-information/abstract-text/34384237/pubmed" id="34384237" target="_blank">34384237</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7379445">
<a name="7379445"></a>Lowenthal DT, Hobbs D, Affrime MB, Twomey TM, Martinez EW, Onesti G. Prazosin kinetics and effectiveness in renal failure. <i>Clin Pharmacol Ther.</i> 1980;27(6):779-783. doi:10.1038/clpt.1980.110<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prazosin-pediatric-drug-information/abstract-text/7379445/pubmed" id="7379445" target="_blank">7379445</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29732214">
<a name="29732214"></a>Lunacek A, Mohamad Al-Ali B, Radmayr C, et al. Ten years of intraoperative floppy iris syndrome in the era of α-blockers. <i>Cent European J Urol</i>. 2018;71(1):98-104. doi:10.5173/ceju.2017.1234<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prazosin-pediatric-drug-information/abstract-text/29732214/pubmed" id="29732214" target="_blank">29732214</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35577426">
<a name="35577426"></a>Magee LA, Smith GN, Bloch C, et al. Guideline no. 426: hypertensive disorders of pregnancy: diagnosis, prediction, prevention, and management. <i>J Obstet Gynaecol Can</i>. 2022;44(5):547-571.e1. doi:10.1016/j.jogc.2022.03.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prazosin-pediatric-drug-information/abstract-text/35577426/pubmed" id="35577426" target="_blank">35577426</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10789664">
<a name="10789664"></a>Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group [published correction appearing in <i>JAMA</i>. 2002;288(23):2976]. <i>JAMA</i>. 2000;283(15):1967-1975.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prazosin-pediatric-drug-information/abstract-text/10789664/pubmed" id="10789664" target="_blank">10789664</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21420124">
<a name="21420124"></a>McVary KT, Roehrborn CG, Avins AL, et al. Update on AUA guideline on the management of benign prostatic hyperplasia. <i>J Urol</i>. 2011;185(5):1793-1803. doi:10.1016/j.juro.2011.01.074<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prazosin-pediatric-drug-information/abstract-text/21420124/pubmed" id="21420124" target="_blank">21420124</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Minipress.2015.02">
<a name="Minipress.2015.02"></a>Minipress (prazosin) [prescribing information]. New York, NY: Pfizer Labs; February 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29852917">
<a name="29852917"></a>Morgenthaler TI, Auerbach S, Casey KR, et al. Position paper for the treatment of nightmare disorder in adults: an American Academy of Sleep Medicine position paper. <i>J Clin Sleep Med</i>. 2018;14(6):1041-1055. doi:10.5664/jcsm.7178<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prazosin-pediatric-drug-information/abstract-text/29852917/pubmed" id="29852917" target="_blank">29852917</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NHLBI.2011">
<a name="NHLBI.2011"></a>National Heart, Lung, and Blood Institute. Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents. Clinical Practice Guidelines, 2011, National Institutes of Health. Accessed March 16, 2012. <a href="http://www.nhlbi.nih.gov/guidelines/cvd_ped/peds_guidelines_full.pdf" target="_blank">http://www.nhlbi.nih.gov/guidelines/cvd_ped/peds_guidelines_full.pdf</a>.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15286277">
<a name="15286277"></a>National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. <i>Pediatrics</i>. 2004;114(2 Suppl 4th Report):555-576.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prazosin-pediatric-drug-information/abstract-text/15286277/pubmed" id="15286277" target="_blank">15286277</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NICE.1">
<a name="NICE.1"></a>National Institute for Health and Care Excellence (NICE) guideline. Hypertension in pregnancy: diagnosis and management. www.nice.org.uk/guidance/ng133. Published June 25, 2019. Accessed December 1, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20935398">
<a name="20935398"></a>Natu VS, Kamerkar SB, Geeta K, et al. Efficacy of anti-scorpion venom serum over prazosin in the management of severe scorpion envenomation. <i>J Postgrad Med</i>. 2010;56(4):275-280. doi:10.4103/0022-3859.70938<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prazosin-pediatric-drug-information/abstract-text/20935398/pubmed" id="20935398" target="_blank">20935398</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6345178">
<a name="6345178"></a>Nielsen SL, Vitting K, Rasmussen K. Prazosin treatment of primary Raynaud's phenomenon. <i>Eur J Clin Pharmacol</i>. 1983;24(3):421-423. doi:10.1007/BF00610065<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prazosin-pediatric-drug-information/abstract-text/6345178/pubmed" id="6345178" target="_blank">6345178</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25073735">
<a name="25073735"></a>Oelke M, Gericke A, Michel MC. Cardiovascular and ocular safety of α1-adrenoceptor antagonists in the treatment of male lower urinary tract symptoms. <i>Expert Opin Drug Saf</i>. 2014;13(9):1187-97. doi:10.1517/14740338.2014.936376<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prazosin-pediatric-drug-information/abstract-text/25073735/pubmed" id="25073735" target="_blank">25073735</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34630699">
<a name="34630699"></a>Pacu I, Zygouropoulos N, Furau CG, et al. Pheochromocytoma as a rare hypertensive complication rarely associated with pregnancy: diagnostic difficulties (review). <i>Exp Ther Med</i>. 2021;22(5):1345. doi:10.3892/etm.2021.10780<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prazosin-pediatric-drug-information/abstract-text/34630699/pubmed" id="34630699" target="_blank">34630699</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27400984">
<a name="27400984"></a>Page RL 2nd, O'Bryant CL, Cheng D, et al; American Heart Association Clinical Pharmacology and Heart Failure and Transplantation Committees of the Council on Clinical Cardiology; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular and Stroke Nursing; and Council on Quality of Care and Outcomes Research. Drugs That May Cause or Exacerbate Heart Failure: A Scientific Statement From the American Heart Association [published correction appears in <i>Circulation</i>. 2016;134(12):e261]. <i>Circulation</i>. 2016;134(6):e32-e69. doi:10.1161/CIR.0000000000000426<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prazosin-pediatric-drug-information/abstract-text/27400984/pubmed" id="27400984" target="_blank">27400984</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24550184">
<a name="24550184"></a>Pandi K, Krishnamurthy S, Srinivasaraghavan R, Mahadevan S. Efficacy of scorpion antivenom plus prazosin versus prazosin alone for <i>Mesobuthus tamulus</i> scorpion sting envenomation in children: a randomised controlled trial. <i>Arch Dis Child</i>. 2014;99(6):575-580. doi:10.1136/archdischild-2013-305483<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prazosin-pediatric-drug-information/abstract-text/24550184/pubmed" id="24550184" target="_blank">24550184</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27551761">
<a name="27551761"></a>Paśko P, Rodacki T, Domagała-Rodacka R, Owczarek D. Interactions between medications employed in treating benign prostatic hyperplasia and food - A short review. <i>Biomed Pharmacother</i>. 2016;83:1141-1145. doi:10.1016/j.biopha.2016.08.021<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prazosin-pediatric-drug-information/abstract-text/27551761/pubmed" id="27551761" target="_blank">27551761</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12967060">
<a name="12967060"></a>Peskind ER, Bonner LT, Hoff DJ, Raskind MA. Prazosin reduces trauma-related nightmares in older men with chronic posttraumatic stress disorder. <i>J Geriatr Psychiatry Neurol</i>. 2003;16(3):165-171. doi:10.1177/0891988703256050<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prazosin-pediatric-drug-information/abstract-text/12967060/pubmed" id="12967060" target="_blank">12967060</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Prazosin.2016.11">
<a name="Prazosin.2016.11"></a>Prazosin capsules [prescribing information]. Morgantown, WV: Mylan Pharmaceuticals Inc.; November 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30165544">
<a name="30165544"></a>Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, et al. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. <i>Eur Heart J</i>. 2018;39(34):3165-3241. doi:10.1093/eurheartj/ehy340<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prazosin-pediatric-drug-information/abstract-text/30165544/pubmed" id="30165544" target="_blank">30165544</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8931848">
<a name="8931848"></a>Rieckert H. Orthostatic hypotension: how to avoid it during antihypertensive therapy. <i>Am J Hypertens</i>. 1996;9(11):155S-159S. doi:10.1016/0895-7061(96)00291-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prazosin-pediatric-drug-information/abstract-text/8931848/pubmed" id="8931848" target="_blank">8931848</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28390429">
<a name="28390429"></a>Rodrigo C, Gnanathasan A. Management of scorpion envenoming: a systematic review and meta-analysis of controlled clinical trials. <i>Syst Rev</i>. 2017;6(1):74. doi:10.1186/s13643-017-0469-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prazosin-pediatric-drug-information/abstract-text/28390429/pubmed" id="28390429" target="_blank">28390429</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6639840">
<a name="6639840"></a>Rubin PC, Butters L, Low RA, Reid JL. Clinical pharmacological studies with prazosin during pregnancy complicated by hypertension. <i>Br J Clin Pharmacol</i>. 1983;16(5):543-547. doi:10.1111/j.1365-2125.1983.tb02213.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prazosin-pediatric-drug-information/abstract-text/6639840/pubmed" id="6639840" target="_blank">6639840</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6131190">
<a name="6131190"></a>Ruzicka T, Ring J. Hypersensitivity to prazosin. <i>Lancet</i>. 1983;1(8322):473-474. doi:10.1016/s0140-6736(83)91469-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prazosin-pediatric-drug-information/abstract-text/6131190/pubmed" id="6131190" target="_blank">6131190</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3884807">
<a name="3884807"></a>Russell IJ, Lessard JA. Prazosin treatment of Raynaud's phenomenon: a double blind single crossover study. <i>J Rheumatol</i>. 1985;12(1):94-98.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prazosin-pediatric-drug-information/abstract-text/3884807/pubmed" id="3884807" target="_blank">3884807</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6162595">
<a name="6162595"></a>Semplicini A, Pessina AC, Palatini P, Hlede M, Palù CD. Orthostatic hypotension after the first administration of prazosin in hypertensive patients: role of the plasma volume. <i>Clin Exp Pharmacol Physiol</i>. 1981;8(1):1-10. doi:10.1111/j.1440-1681.1981.tb00127.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prazosin-pediatric-drug-information/abstract-text/6162595/pubmed" id="6162595" target="_blank">6162595</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18388959">
<a name="18388959"></a>Shah N, Tendulkar M, Brown R. Should we anticipate intraoperative floppy iris syndrome (IFIS) even with very short history of tamsulosin? <i>Eye (Lond)</i>. 2009;23(3):740. doi:10.1038/eye.2008.95<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prazosin-pediatric-drug-information/abstract-text/18388959/pubmed" id="18388959" target="_blank">18388959</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8417406">
<a name="8417406"></a>Sinaiko AR. Pharmacologic management of childhood hypertension [published correction appearing in <i>Pediatr Clin North Am.</i> 1993;40(4):following viii]. <i>Pediatr Clin North Am</i>. 1993;40(1):195-212. doi:10.1016/s0031-3955(16)38490-5.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prazosin-pediatric-drug-information/abstract-text/8417406/pubmed" id="8417406" target="_blank">8417406</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27828694">
<a name="27828694"></a>Singh B, Hughes AJ, Mehta G, Erwin PJ, Parsaik AK. Efficacy of Prazosin in Posttraumatic Stress Disorder: A Systematic Review and Meta-Analysis. <i>Prim Care Companion CNS Disord</i>. 2016;18(4). doi:10.4088/PCC.16r01943.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prazosin-pediatric-drug-information/abstract-text/27828694/pubmed" id="27828694" target="_blank">27828694</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6367665">
<a name="6367665"></a>Surwit RS, Gilgor RS, Allen LM, Duvic M. A double-blind study of prazosin in the treatment of Raynaud's phenomenon in scleroderma. <i>Arch Dermatol</i>. 1984;120(3):329-331.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prazosin-pediatric-drug-information/abstract-text/6367665/pubmed" id="6367665" target="_blank">6367665</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17868655">
<a name="17868655"></a>Taylor FB, Martin P, Thompson C, et al. Prazosin effects on objective sleep measures and clinical symptoms in civilian trauma posttraumatic stress disorder: a placebo-controlled study. <i>Biol Psychiatry</i>. 2008;63(6):629-632. doi:10.1016/j.biopsych.2007.07.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prazosin-pediatric-drug-information/abstract-text/17868655/pubmed" id="17868655" target="_blank">17868655</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21730810">
<a name="21730810"></a>Tuuri RE, Reynolds S. Scorpion envenomation and antivenom therapy. <i>Pediatr Emerg Care</i>. 2011;27(7):667-672; quiz 673-5. doi:10.1097/PEC.0b013e3182228dfa<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prazosin-pediatric-drug-information/abstract-text/21730810/pubmed" id="21730810" target="_blank">21730810</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15617511">
<a name="15617511"></a>Ursano RJ, Bell C, Eth S, et al; Work Group on ASD and PTSD; Steering Committee on Practice Guidelines. Practice guideline for the treatment of patients with acute stress disorder and posttraumatic stress disorder. <i>Am J Psychiatry</i>. 2004;161(11 suppl):3-31.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prazosin-pediatric-drug-information/abstract-text/15617511/pubmed" id="15617511" target="_blank">15617511</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-VADoD.2017">
<a name="VADoD.2017"></a>US Department of Veterans Affairs/Department of Defense (VA/DoD). VA/DoD clinical practice guideline for the management of posttraumatic stress disorder and acute stress disorder. Updated June 2017. Accessed November 9, 2018. <a href="https://www.healthquality.va.gov/guidelines/MH/ptsd/VADoDPTSDCPGFinal012418.pdf" target="_blank">https://www.healthquality.va.gov/guidelines/MH/ptsd/VADoDPTSDCPGFinal012418.pdf</a>.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24341872">
<a name="24341872"></a>Weber MA, Schiffrin EL, White WB, et al, Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. <i>J Clin Hypertens (Greenwich)</i>. 2014;16(1):14-26. doi:10.1111/jch.12237<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prazosin-pediatric-drug-information/abstract-text/24341872/pubmed" id="24341872" target="_blank">24341872</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29133354">
<a name="29133354"></a>Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. <i>Hypertension</i>. 2018;71(6):1269-1324. doi:10.1161/HYP.0000000000000066<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prazosin-pediatric-drug-information/abstract-text/29133354/pubmed" id="29133354" target="_blank">29133354</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12324557">
<a name="12324557"></a>Wigley FM. Clinical practice. Raynaud's phenomenon. <i>N Engl J Med</i>. 2002;347(13):1001-1008. doi:10.1056/NEJMcp013013<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prazosin-pediatric-drug-information/abstract-text/12324557/pubmed" id="12324557" target="_blank">12324557</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3243924">
<a name="3243924"></a>Wollersheim H, Thien T. Dose-response study of prazosin in Raynaud's phenomenon: clinical effectiveness versus side effects. <i>J Clin Pharmacol</i>. 1988;28(12):1089-1093. doi:10.1002/j.1552-4604.1988.tb05720.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prazosin-pediatric-drug-information/abstract-text/3243924/pubmed" id="3243924" target="_blank">3243924</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3731684">
<a name="3731684"></a>Wollersheim H, Thien T, Fennis J, van Elteren P, van 't Laar A. Double-blind, placebo-controlled study of prazosin in Raynaud's phenomenon. <i>Clin Pharmacol Ther</i>. 1986;40(2):219-225. doi:10.1038/clpt.1986.166<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prazosin-pediatric-drug-information/abstract-text/3731684/pubmed" id="3731684" target="_blank">3731684</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24917702">
<a name="24917702"></a>Zaman F, Bach C, Junaid I, et al. The floppy iris syndrome - what urologists and ophthalmologists need to know. <i>Curr Urol</i>. 2012;6(1):1-7. doi:10.1159/000338861<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/prazosin-pediatric-drug-information/abstract-text/24917702/pubmed" id="24917702" target="_blank">24917702</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 12722 Version 362.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
